|
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Helicobacter pylori quantity and HP-NAP gene expression were evaluated in the faeces of healthy and asthmatic children.
|
28579087 |
2018 |
|
Colorectal Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex.
|
19082443 |
2009 |
|
Lung Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Moreover, rMBP-NAP also showed significant anti-angiogenic activity by reducing vascularization in lung tumor sections. rMBP-NAP could induce antitumor immunity through activating Th1 cells and producing pro-inflammatory cytokines, which are responsible for the effective cytotoxic immune response against cancer progression.
|
28863272 |
2018 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
LHGDN |
Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex.
|
19082443 |
2009 |
|
Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Of these four proteins, EEA1 and PI3KR2 were down-regulated after NAP-induced neuroprotective activity in neuroblastoma cells.
|
30987727 |
2019 |
|
Zinc deficiency
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The resulting Zn deficiency leads, through its metalloenzymes, to a low NAP activity and depressed DNA & RNA polymerase activities: the latter necessitates an adaptive mechanism to sustain cell division despite low zinc.
|
7666834 |
1995 |
|
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Toll-like receptor agonist rMBP-NAP enhances antitumor cytokines production and CTL activity of peripheral blood mononuclear cells from patients with lung cancer.
|
30214604 |
2018 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Toll-like receptor agonist rMBP-NAP enhances antitumor cytokines production and CTL activity of peripheral blood mononuclear cells from patients with lung cancer.
|
30214604 |
2018 |
|
Central neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Of these four proteins, EEA1 and PI3KR2 were down-regulated after NAP-induced neuroprotective activity in neuroblastoma cells.
|
30987727 |
2019 |
|
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Toll-like receptor agonist rMBP-NAP enhances antitumor cytokines production and CTL activity of peripheral blood mononuclear cells from patients with lung cancer.
|
30214604 |
2018 |
|
Childhood Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Of these four proteins, EEA1 and PI3KR2 were down-regulated after NAP-induced neuroprotective activity in neuroblastoma cells.
|
30987727 |
2019 |
|
Malignant neoplasm of prostate
|
0.110 |
Biomarker
|
disease |
BEFREE |
Label-free quantification of EVs was performed to identify differentially expressed proteins between PCa and NAP.
|
31018022 |
2019 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effect of NAP on Abeta and tau pathology using a transgenic mouse model that recapitulates both aspects of AD.
|
17478890 |
2007 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Addressing Alzheimer's disease tangles: from NAP to AL-108.
|
19874271 |
2009 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Thus, aluminum ions may increase the risk for neurotoxicity in AD, and the use of NAP is suggested as a treatment to provide additional protection against the effects of aluminum ions, via EEA1 and PI3KR2, associated with sorting and processing of the AD amyloid precursor protein (APP) through the endosomal system.
|
30987727 |
2019 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity.
|
18325910 |
2008 |
|
Diabetic Retinopathy
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, deepened characterization of NAP action mechanism on hyperglycemic-inflammatory damage may be useful to develop a new strategy to prevent retinal damage during DR.
|
30374973 |
2019 |
|
Diabetic Retinopathy
|
0.020 |
Biomarker
|
disease |
BEFREE |
More recently, we have shown that a small peptide derived from the activity-dependent neuroprotective protein (ADNP), known as NAP, counteracts damages occurring during progression of diabetic retinopathy by modulating HIFs/VEGF pathway.
|
28436035 |
2018 |
|
Impaired cognition
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, the combination of NAP and standard of care Risperidone in humans may protect against language disturbances associated with negative and cognitive impairments in schizophrenia.
|
26553741 |
2015 |
|
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
|
0.020 |
Biomarker
|
disease |
BEFREE |
To detect and evaluate the antibodies against Helicobacter pylori (H pylori) neutrophil-activating protein (HP-NAP) in patients with gastric cancer and other gastroduodenal diseases.
|
19452583 |
2009 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Spliceosome-associated factor CTNNBL1 promotes proliferation and invasion in ovarian cancer.
|
28501461 |
2017 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
LHGDN |
Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.
|
19148501 |
2009 |
|
Tauopathies
|
0.020 |
Biomarker
|
group |
BEFREE |
Here, we examined the potential preferential interaction of NAP with 3R vs. 4R Tau, toward personalized treatment of tauopathies.
|
30865715 |
2019 |
|
Tauopathies
|
0.020 |
Biomarker
|
group |
BEFREE |
We previously investigated the disease-modifying potential of a microtubule-stabilising peptide NAP (NAPVSIPQ) in a well-established Drosophila model of tauopathy characterised by microtubule breakdown and axonal transport deficits.
|
27910888 |
2016 |
|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage.
|
17478890 |
2007 |